Cspc Pharmaceutgr Adr4 Stock Gross Profit

CVGU Stock  EUR 2.32  0.02  0.87%   
CSPC PHARMACEUTGR ADR4 fundamentals help investors to digest information that contributes to CSPC PHARMACEUTGR's financial success or failures. It also enables traders to predict the movement of CSPC Stock. The fundamental analysis module provides a way to measure CSPC PHARMACEUTGR's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CSPC PHARMACEUTGR stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

CSPC PHARMACEUTGR ADR4 Company Gross Profit Analysis

CSPC PHARMACEUTGR's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Gross Profit

 = 

Revenue

-

Cost of Revenue

More About Gross Profit | All Equity Analysis

Current CSPC PHARMACEUTGR Gross Profit

    
  21.14 B  
Most of CSPC PHARMACEUTGR's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CSPC PHARMACEUTGR ADR4 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Competition

According to the company disclosure, CSPC PHARMACEUTGR ADR4 reported 21.14 B of gross profit. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The gross profit for all Germany stocks is 22.8% higher than that of the company.

CSPC Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CSPC PHARMACEUTGR's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CSPC PHARMACEUTGR could also be used in its relative valuation, which is a method of valuing CSPC PHARMACEUTGR by comparing valuation metrics of similar companies.
CSPC PHARMACEUTGR is rated below average in gross profit category among its peers.

CSPC Fundamentals

About CSPC PHARMACEUTGR Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze CSPC PHARMACEUTGR ADR4's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CSPC PHARMACEUTGR using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CSPC PHARMACEUTGR ADR4 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in CSPC Stock

CSPC PHARMACEUTGR financial ratios help investors to determine whether CSPC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CSPC with respect to the benefits of owning CSPC PHARMACEUTGR security.